Phaseline

Targets › METTL3

METTL3 (N(6)-adenosine-methyltransferase catalytic subunit METTL3): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Nov 2027.

The METTL3-METTL14 heterodimer forms a N6-methyltransferase complex that methylates adenosine residues at the N(6) position of some RNAs and regulates various processes such as the circadian clock, differentiation of embryonic and hematopoietic stem cells, cortical neurogenesis, response to DNA damage, differentiation of T-cells and primary miRNA processing. In the heterodimer formed with METTL14, METTL3 constitutes…. (UniProt, Q86U44)

Open in Phaseline: the race on METTL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Epics TherapeuticsEP102
METTL3 modulator
METTL3Phase 1Advanced Solid Tumor (Phase 1)Nov 2027
STORM TherapeuticsSTC-15
METTL3 inhibitor
METTL3Phase 1Solid TumorDec 2027

Conditions

Advanced Solid Tumor (Phase 1) (1) Solid Tumor (1)

Modalities

small molecule (1), mixed (1)

Companies

Epics Therapeutics (1) STORM Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.